The estimated Net Worth of David Allen Weber is at least $2.23 Milhão dollars as of 25 March 2022. David Weber owns over 19,269 units of Otonomy Inc stock worth over $29,067 and over the last 10 years he sold OTIC stock worth over $46,246. In addition, he makes $2,153,120 as President, Chief Executive Officer, e Director at Otonomy Inc.
David has made over 7 trades of the Otonomy Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 19,269 units of OTIC stock worth $46,246 on 25 March 2022.
The largest trade he's ever made was selling 19,269 units of Otonomy Inc stock on 25 March 2022 worth over $46,246. On average, David trades about 2,654 units every 113 days since 2014. As of 25 March 2022 he still owns at least 377,499 units of Otonomy Inc stock.
You can see the complete history of David Weber stock trades at the bottom of the page.
Dr. David A. Weber Ph.D. serves as President, Chief Executive Officer, Director of the Company. Prior to joining us, Dr. Weber served from February 2004 to April 2010 as the Chief Executive Officer of MacuSight, Inc., a developer of a sustained delivery formulation of sirolimus for the treatment of severe ophthalmic diseases. Prior to MacuSight, Dr. Weber served as acting Chief Executive Officer and Executive Vice President of Oculex Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of intraocular pharmaceuticals and drug delivery systems, until its acquisition by Allergan in 2003. Dr. Weber has also held management positions with Oral-B Laboratories, a developer and manufacturer of oral hygiene products, and with Procter & Gamble, Co., a consumer products company. Dr. Weber has served on the board of directors of Oculis, a clinical stage ophthalmic biotechnology company, since September 2018. From October 2009 to July 2014, Dr. Weber served on the board of directors of On Demand Therapeutics, Inc., a medical device company. Dr. Weber received his Ph.D. in medical microbiology from Creighton University and his Master’s and Bachelor’s degrees in biological sciences from Wichita State University.
As the President, Chief Executive Officer, e Director of Otonomy Inc, the total compensation of David Weber at Otonomy Inc is $2,153,120. There are no executives at Otonomy Inc getting paid more.
David Weber is 60, he's been the President, Chief Executive Officer, e Director of Otonomy Inc since 2010. There are 4 older and 9 younger executives at Otonomy Inc. The oldest executive at Otonomy Inc is James Breitmeyer, 66, who is the Independent Director.
David's mailing address filed with the SEC is C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121.
Over the last 10 years, insiders at Otonomy Inc have traded over $30,282,796 worth of Otonomy Inc stock and bought 755,065 units worth $12,114,945 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Holdings A/S Novo, eBrian H Dovey. On average, Otonomy Inc executives and independent directors trade stock every 66 days with the average trade being worth of $7,317. The most recent stock trade was executed by Vickie L Capps on 28 November 2022, trading 42,242 units of OTIC stock currently worth $4,224.
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière's disease, hearing loss, and tinnitus.
Otonomy Inc executives and other stock owners filed with the SEC include: